Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation by Sordi, Regina et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Sordi, Regina; Nandra, Kiran K.; Chiazza, Fausto; Johnson, Florence L.;
Cabrera, Claudia P.; Torrance, Hew D.; Yamada, Noriaki; Patel, Nimesh S.
A.; Barnes, Michael R.; Brohi, Karim; Collino, Massimo; Thiemermann,
Christoph. Artesunate Protects Against the Organ Injury and Dysfunction
Induced by Severe Hemorrhage and Resuscitation. ANNALS OF SURGERY.
None pp: 1--.
DOI: 10.1097/SLA.0000000000001664
The publisher's version is available at:
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000658-900000000-96827
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1610609
1 
 
 
 
Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe 
Haemorrhage and Resuscitation 
Regina Sordi, PhD*,1, Kiran K Nandra, PhD*,1, Fausto Chiazza, BSc2, Claudia P Cabrera, 
PhD3, Hew Torrance, MD4, Nimesh S A Patel, PhD1, Michael R Barnes, PhD3, Karim Brohi, 
MD4, Massimo Collino, PhD2 and Christoph Thiemermann, MD, PhD1 
 
* These authors contributed equally to this work 
1Department of Translational Medicine and Therapeutics, William Harvey Research Institute, 
Barts and The London School of Medicine & Dentistry, Queen Mary University of London, 
London, UK. 
2Department of Drug Science and Technology, University of Turin, Turin, Italy. 
3Department of Clinical Pharmacology, William Harvey Research Institute, Barts and The 
London School of Medicine & Dentistry, Queen Mary University of London, London, UK. 
4Centre for Trauma Sciences, Blizzard Institute, Barts and The London School of Medicine & 
Dentistry, Queen Mary University of London, London, UK. 
 
Conflicts of interest and source of funding: 
CT is inventor on a patent relating to the use of artesunate in haemorrhagic shock (United States 
Application No: 14/125032). RS is supported by the Program Science without Borders, CAPES 
Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil; NSAP is, in part, supported 
by the Bart’s and The London Charity (753/1722). The research leading to these results has 
received funding from the People Programme (Marie Curie Actions) of the European Union’s 
Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no 608765, 
from the William Harvey Research Foundation and the University of Turin (Ricerca Locale ex-
60%). This work contributes to the Organ Protection research theme of the Barts Centre for 
Trauma Sciences, supported by the Barts and The London Charity (Award 753/1722) and forms 
part of the research themes contributing to the translational research portfolio of Barts and the 
2 
 
 
 
London Cardiovascular Biomedical Research Unit which is supported and funded by the 
National Institute of Health Research. The funders had no role in study design, data collection 
and analysis, decision to publish, or preparation of the manuscript. 
 
Corresponding author and reprints: 
Professor Christoph Thiemermann, MD PhD FBPhS FRCP FMedSci  
William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, 
Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. 
Phone: + 44 (0) 20 7882 8180 
E-mail: c.thiemermann@qmul.ac.uk 
 
 
Running head: Artesunate reduces MOF in haemorrhagic shock 
 
 
 
 
 
 
 
 
 
 
Mini-Abstract 
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The anti-malarial drug artesunate reduces the organ injury/dysfunction caused by haemorrhagic 
shock in rats. A similar dose of artesunate improves survival in patients with severe malaria 
with multiple organ injury/failure without causing any significant adverse effects. A phase II 
clinical trial evaluating the effects of artesunate in trauma/haemorrhage is planned.    
 
Structured Abstract 
Objective: To evaluate the effects of artesunate on organ injury and dysfunction associated 
with HS in the rat. 
Summary Background Data: Haemorrhagic shock (HS) is still a common cause of death in 
severely injured patients and it is characterized by impairment of organ perfusion, systemic 
inflammatory response and multiple organ failure. There is no specific therapy that reduces 
organ injury/dysfunction. Artesunate exhibits pharmacological actions beyond its antimalarial 
activity, such as anti-cancer, anti-viral and anti-inflammatory effects.  
Methods: Rats were submitted to HS. Mean arterial pressure was reduced to 30 mmHg for 90 
min, followed by resuscitation. Rats were randomly treated with artesunate (2.4 or 4.8 mg/kg 
i.v.) or vehicle upon resuscitation. Four hours later, parameters of organ injury and dysfunction 
were assessed.  
Results: Artesunate attenuated the multiple organ injury and dysfunction caused by HS. 
Pathway analysis of RNAseq provided good evidence to support an effect of artesunate on the 
Akt-survival pathway, leading to down-regulation of IRAK1. Using Western blot analysis, we 
confirmed that treatment of HS-rats with artesunate enhanced the phosphorylation (activation) 
of Akt and eNOS and the phosphorylation (inhibition) of glycogen synthase kinase-3β (GSK-
3β). Moreover, artesunate attenuated the HS-induced activation of NF-κB and reduced the 
expression of pro-inflammatory proteins (iNOS, TNF-α and IL-6).  
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Conclusions: Artesunate attenuated the organ injury/dysfunction associated with HS by a 
mechanism that involves the activation of the Akt-eNOS survival pathway, and the inhibition 
of GSK-3β and NF-κB. A phase II clinical trial evaluating the effects of GMP-artesunate in 
patients with trauma and severe haemorrhage is planned. 
 
Keywords: haemorrhagic shock, organ injury, artesunate, anti-malarial, Akt, NF-κB. 
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine 
kinase; DHA, dihydroartemisinin; eNOS, endothelial nitric oxide synthase; FOXO4, forkhead 
box O4; GSK-3β, glycogen synthase kinase-3β; HS, haemorrhagic shock; IL-6, interleukin 6; 
IRAK1, interleukin-1 receptor-associated kinase 1; MAP, mean arterial pressure; MOF, 
multiple organ failure; MPO, myeloperoxidase; NF-κB, nuclear factor kappa B; TNF-α, tumour 
necrosis factor-α; WHO, World Health Organization. 
 
 
 
 
 
 
INTRODUCTION 
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Trauma is a leading cause of death with 5 million of victims yearly. About 40% of trauma 
deaths are due to haemorrhagic shock (HS), which causes hypoperfusion of organs leading to 
multiple organ failure (MOF).1 The development of MOF occurs in approximately 30% of  
injured patients, and is the major cause of morbidity following trauma.2 The development of 
MOF correlates with an increase in nosocomial infections and, if it persists, mortality.3 The 
mechanisms underlying the MOF are not fully understood, although ischaemia-reperfusion 
injury and systemic inflammation are likely to be key players.4 There are no specific treatments 
for the MOF associated with HS, thus, a therapeutic agent that reduces the incidence and 
severity of MOF is urgently needed and could have a major global impact on patient outcomes. 
Artesunate (a semi-synthetic artemisinin derived from the plant Artemisia annua) is 
recommended by the World Health Organization (WHO) as the treatment of choice for severe 
malaria.5 Artesunate is a safe, low-cost and well tolerated drug and has been used by thousands 
of patients with malaria without important adverse effects.6 Although the mechanism behind 
the antimalarial activity of artesunate is not entirely clear, it is thought that the active metabolite, 
dihydroartemisinin (DHA) is responsible for the death of the parasite possibly through the 
inhibition of the parasitic calcium pump.7 
Artemisinins, including artesunate, have many pharmacological effects beyond the eradication 
of Plasmodium species.8 Artemisinins/artesunate have demonstrated cytotoxic effects against 
cancer cells,9 viruses,10 fungi,11 but also powerful anti-inflammatory effects in animal models 
of asthma,12 pancreatitis,13 arthritis14 and sepsis,15 to name but a few. However, the effects of 
artesunate in HS, a condition associated with ischaemia and reperfusion injury, are unknown. 
Therefore, the aim of the present study was to investigate the effects of artesunate on the organ 
injury and dysfunction associated with HS. Having discovered that artesunate attenuates the 
organ injury and dysfunction associated with HS, we have then carried out an extensive 
evaluation of the potential mechanism of action of artesunate, including RNAseq 
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transcriptomics and pathway analysis. We report here for the first time that artesunate has pro-
survival and anti-inflammatory properties, as it activates the Akt-eNOS cell survival pathway 
and inhibits a range of proinflammatory molecules, including IRAK1, FOXO4, GSK-3β and 
the transcription factor NF-κB. 
 
METHODS 
Animal welfare and ethical statements 
The animal protocols used in this study were approved by the Animal Welfare Ethics Review 
Board (AWERB) of Queen Mary University of London (PPL: 70/7348) in accordance with 
Home Office guidance on Operation of Animals (Scientific Procedures Act 1986) and Guide 
for the Care and Use of Laboratory Animals of the National Research Council. 
 
Haemorrhagic shock and quantification of organ injury and dysfunction 
This study was carried out on 50 male Wistar rats (Charles River Ltd, Margate, UK) weighing 
280 ± 20 g receiving a standard diet and water ad libitum. Hemorrhagic shock was performed 
as previously described.16 Rats were anaesthetized using sodium thiopentone (120 mg/kg i.p. 
maintained using 10 mg/kg i.v.) and cannulation of the trachea, femoral and carotid arteries, 
jugular vein and bladder was performed. Blood was withdrawn in order to achieve a fall in 
mean arterial pressure (MAP) to 30 ± 2 mmHg, which was maintained for a period of 90 
minutes. Resuscitation was performed with the remained shed blood. An infusion of Ringer 
Lactate (1.5 mL/kg/hour; i.v.) was maintained throughout the experiment for a total of 4 hours. 
The last 3 hours urine was obtained for the estimation of creatinine clearance. Blood samples 
were collected via the carotid artery for measurement of lactate (Accutrend Plus Meter, Roche 
Diagnostics, West Sussex, UK) and organ injury parameters [creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), lipase, amylase and creatine kinase 
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(CK) (IDEXX Laboratories Ltd, West Yorkshire, UK)]. In addition, lung, kidney and liver 
samples were taken and stored at -80 oC for further analysis. Sham-operated rats were used as 
control and underwent identical surgical procedures but without haemorrhage or resuscitation. 
 
Experimental design 
Rats were randomly allocated into the following groups (n = 10 per group): sham + vehicle; 
sham + artesunate 4.8 mg/kg; HS + vehicle; HS + artesunate 2.4 mg/kg and HS + artesunate 
4.8 mg/kg. Rats were administered vehicle (PBS; pH 8; 1 mL/kg) or artesunate (2.4 mg/mL/kg 
or 4.8 mg/mL/kg) i.v. upon resuscitation.  
 
Determination of myeloperoxidase (MPO) activity 
Samples were homogenized in phosphate buffer and centrifuged at 4oC. Pellets were re-
suspended in a 0.5% hexadecyltrimethylammonium bromide 50 mM phosphate buffer solution, 
sonicated and put in ice for 20 minutes.  After 15 minutes of centrifuge (13,000 g at 4oC), 
supernatant was allowed to react with a solution of o-Dianisidine (0.167 mg/mL) and H2O2 
(0.0005%) in 50mM phosphate buffer. The rate of change in absorbance was measured 
spectrophotometrically at 460 nm. Myeloperoxidase activity was defined as the quantity of 
enzyme degrading 1 µmol of peroxide per minute and was expressed in milliunits per gram of 
wet tissue. 
 
RNA sequencing analysis 
Gene expression was evaluated by RNA sequencing (RNA-seq) which allows a dynamic range 
of detection and measurement of relatively limited differences in expression between samples. 
Whole blood RNA samples were extracted from 12 rats (3 samples per group). 1 μg of total 
RNA was used for library preparation, according to the Illumina TruSeq mRNA sample 
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preparation protocol (Illumina, San Diego, Calif). Libraries were sequenced using Illumina 
NextSeq platform and TruSeq protocol. Adaptor and poor quality sequences were removed 
using trim galore (v0.3.7) software. Trimmed sequences were aligned to the rat reference 
genome (rnor5) with TopHat2 (v2.0.13)/bowtie2 (v2.2.3). Read counts were calculated using 
the HTSeq-counts program and differential expression analyses were carried out with DESeq2, 
using the standard protocols. Pathway analysis was performed using Enrichr17 and Ingenuity 
Pathway Analysis (http://www.ingenuity.com/). 
 
Western blot 
Samples were homogenized, centrifuged and the supernatants were removed and centrifuged at 
16,000 g at 4°C for 40 minutes to obtain the cytosolic fraction. The pelleted nuclei were 
suspended in extraction buffer and centrifuged. The supernatants were removed, and protein 
content was determined on both nuclear and cytosolic extracts using bicinchoninic acid protein 
assay (Thermo Fisher Scientific Inc, Rockford, IL). Proteins were separated by 8% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a 
polyvinyldenedifluoride membrane, which was then incubated with a primary antibody [total 
Akt (1:1000); pAkt Ser473 (1:1000); total eNOS (1:200), peNOS Ser1177 (1:200); total GSK-3β 
(1:200); pGSK-3β Ser9 (1:200); NF-κB p65 (1:1000) and iNOS (1:200)]. Membranes were 
incubated with secondary antibody conjugated with horseradish peroxidase (1:2000) and 
developed using ECL detection system. The immunoreactive bands were visualised by 
autoradiography. The membranes were stripped and incubated with β-actin monoclonal 
antibody (1:5000) and subsequently with an anti-mouse antibody (1:10000) to assess gel-
loading homogeneity. The densitometric analysis was performed using Gel Pro Analyzer 4.5, 
2000 software (Media Cybernetics, Silver Spring, MD, USA) and is expressed as relative 
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optical density, corrected for the corresponding β-actin contents, and normalized using the 
related mean sham-operated band. 
 
Cytokines  
Serum cytokines TNF-α and IL-6 were determined using commercial immunoassay kits (R&D 
Systems, Minneapolis, MN) according to the manufacturer protocol. 
 
Materials 
Unless otherwise stated, all compounds were obtained from Sigma-Aldrich Company Ltd 
(Poole, Dorset, U.K.). Ringer’s Lactate was obtained from Baxter Healthcare Ltd.; sodium 
thiopentone (Thiovet©) from Link Pharmaceuticals, Horsham, U.K. The bicinchoninic acid 
protein assay kit and SuperBlock blocking buffer were from Thermo Fisher Scientific Inc. 
(Rockford, IL, USA). Antibodies were from Cell Signalling Technology Inc. (Beverly, MA, 
USA).  
 
Data analysis 
All values described in the text and figures are expressed as mean ± SEM. Statistical analysis 
was carried out using GraphPad Prism 5.03 (GraphPad Software, San Diego, California, USA). 
Data were assessed by one or two-way ANOVA followed by Bonferroni’s post hoc test. A p 
value of less than 0.05 was considered to be significant. 
 
 
RESULTS 
Artesunate attenuates the organ injury and dysfunction induced by HS  
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Rats subjected to HS exhibited a significant decrease in creatinine clearance (Fig. 1A), as well 
as a rise in serum creatinine (Fig. 1B) indicating the development of renal dysfunction. HS-rats 
also developed significant increases in AST (Fig. 1C), ALT (Fig. 1D), amylase (Fig. 1E), lipase 
(Fig. 1F), CK (Fig. 1G) and lactate (Fig. 1H), indicating the development of liver, pancreas and 
neuromuscular injury, and global ischaemia, respectively (Fig. 1). 
The treatment of HS-rats with either 2.4 mg/kg or 4.8 mg/kg artesunate significantly attenuated 
the fall in creatinine clearance (Fig. 1A) and attenuated the rises in serum creatinine (Fig. 1B), 
AST (Fig. 1C) and CK (Fig. 1G) when compared to HS-rats treated with vehicle. However, 
when compared to vehicle HS-rats, only the treatment of HS-rats with 4.8 mg/kg artesunate 
attenuated the HS-induced rise in serum levels of ALT (Fig. 1D), amylase (Fig. 1E) and lactate 
(Fig. 1H). The higher dose of artesunate in sham-operated rats had no significant effect on any 
of the parameters evaluated. 
When compared to sham-operated rats, HS-rats developed a significant increase in lung MPO 
activity (Fig. 2) indicating the infiltration of inflammatory cells. Treatment of HS-rats with both 
doses of artesunate significantly attenuated the rise in MPO activity in the lung (Fig. 2). The 
administration of the higher dose of artesunate in sham-operated rats had no significant effect 
on MPO activity. 
 
Artesunate does not prevent the development of the circulatory failure induced by HS  
When compared to sham-operated rats (open circles), HS-rats treated with vehicle 
demonstrated a significant reduction in MAP after resuscitation (closed squares; Fig. 3). The 
administration of artesunate (2.4 or 4.8 mg/kg; closed triangles) on resuscitation failed to 
attenuate the reduction in MAP caused by HS (Fig. 3). The administration of artesunate (4.8 
mg/kg) in sham-operated rats had no significant effect on the hemodynamic function (closed 
diamonds). 
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Artesunate acts predominantly on the AKT-survival pathway 
RNAseq transcriptome sequencing was performed on white blood cells. Differential expression 
analysis identified a large number of differentially expressed transcripts between treatment 
groups (Supplementary Table 1). Enrichr pathway analysis of genes showing differential 
expression in both the sham and HS-rats, identified AKT1 protein interaction as the strongest 
enrichment on a genome wide basis (10/119 genes; adjusted p value = 0.00116; Fig. 4A; 
Supplementary Table 1). The AKT1 interactor genes identified in the analysis were PPM1A, 
IRAK1, AKT2, ITGB3, LMNA, NCOA4, BPGM, FOXO4, BCL2L1 and CDC25B. To 
investigate the possible mechanistic basis of AKT1 interaction further, we constructed a 
mechanistic model of differentially expressed direct AKT1 interactors using the molecule 
activity predictor algorithm in Ingenuity Pathway analysis (IPA).18 The algorithm predicted 
AKT activation (Fig. 4B), on the basis of down regulation of a number of genes in the AKT 
core network that are known to be down-regulated by AKT, including IL-1 receptor-associated 
kinase 1 (IRAK1) and forkhead box O4 (FOXO4).  
 
Artesunate attenuates the activation of NF-κB pathway induced by HS  
As we had some evidence to support the action of artesunate on the Akt-survival pathway (Fig. 
4), and as the most striking beneficial effects of artesunate in organ protection were observed in 
liver and kidney (Fig. 1), we subsequently investigated the possible mechanisms by which 
artesunate (4.8 mg/kg) attenuated the organ injury and dysfunction in liver and kidney biopsies. 
When compared to sham-operated rats, HS-rats treated with vehicle exhibited a trend but do not 
show significantly differences in the phosphorylation of Akt on Ser473 (Figs 5A, 6A), eNOS on 
Ser1177 (Figs 5B, 6B) or GSK-3β on Ser9 (Figs 5C, 6C) in liver or kidney, respectively. On the 
other hand, HS-rats exhibited an increase in the nuclear translocation of the p65 NF-κB subunit 
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(Figs 5D, 6D). When compared to HS-rats treated with vehicle, HS-rats treated with artesunate 
significantly increased the phosphorylation of Akt (Figs 5A, 6A), eNOS (Figs 5B, 6B), GSK-
3β (Figs 5C, 6C) and attenuated the subsequent translocation of the p65 NF-κB subunit to the 
nucleus (Figs 5D, 6D). The treatment of sham-rats with artesunate had no significant effect (Figs 
5, 6).  
 
Effects of IKK16 treatment on iNOS expression and cytokines formation induced by HS 
As we have found a decrease in NF-κB pathway, and iNOS is regulated by this transcription 
factor, we investigated the expression of iNOS in HS-rats. When compared with sham-operated 
rats, livers and kidneys from rats submitted to HS (treated with vehicle) exhibited a significant 
increase in iNOS expression (Fig. 7A, B, respectively). The treatment of HS-rats with artesunate 
at the onset of resuscitation significantly attenuated iNOS expression in both tissues (Fig. 7A, 
B). 
When compared to sham-operated rats, HS-rats treated with vehicle developed significant 
serum increases in the pro-inflammatory cytokines TNF-α (Fig. 7C) and IL-6 (Fig. 7D). The 
treatment of HS-rats with artesunate significantly reduced the rises in serum TNF-α and IL-6 
(Fig. 7C, D). The treatment of sham-rats with artesunate had no significant effect.  
 
 
DISCUSSION 
The main finding of the present report is that the safe antimalarial drug artesunate attenuates 
the organ injury and dysfunction associated with HS. We have discovered that administration 
of artesunate upon resuscitation reduces the MOF by enhancing the resistance of organs against 
injury/dysfunction by activating a well-known cell survival pathway and reducing excessive 
inflammation. The lower dose of artesunate shown here to be effective in HS (e.g. 2.4 mg/kg) 
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is identical to the dose used as an i.v. bolus injection in patients with malaria, many of which 
also have multiple organ dysfunction. Indeed, in these patients artesunate is superior to quinine 
in improving survival.6 
In order to gain a better insight into the potential mechanism of action of artesunate in HS, we 
carried out a controlled RNAseq transcriptome analysis of white blood cells. Pathway analysis 
of genes showing differential expression in both sham and HS-rats, were strongly enriched for 
AKT1 interactor genes. Although AKT1 itself was not differentially expressed, this does not 
reflect protein activity and a mechanistic model of the AKT1 core network predicted AKT 
activation, on the basis of down regulation of several pro-inflammatory genes in the AKT core 
network that are known to be down-regulated by AKT. These include IRAK1 and FOXO4. 
IRAK1 is a signalling molecule that induces nuclear translocation of NF-κB and activator 
protein (AP)-1, resulting in the production of inflammatory cytokines such as TNF-α and IL-
6.19 Previous studies have reported that down regulation of IRAK1 is protective in 
ischemia/reperfusion injury.20 Similarly, FOXO4 specifically activates MMP9 expression in 
response to TNF-α, acting as a convergence point of cytokine and growth factor signalling 
pathways, leading to the proposal that inhibition (or down-regulation as seen in artesunate 
treatment) of FOXO4 could provide a therapeutic target for inflammatory arterial diseases.21 
In our gene expression studies we also observed a decrease in gene expression of MEMO1 in 
sham-operated animals and in HS-rats (data not shown). This finding was somewhat 
contradictory to the hypothesis of AKT activation, as the protein has been shown to activate the 
Akt pathway.22 Subsequently, we have evaluated MEMO1 by Western Blot analysis, and found 
a consistent increase in MEMO1 protein, confirming that artesunate does indeed enhance the 
expression of MEMO1 protein in liver/kidney of sham and HS-rats (data not shown). The 
observed reduction in MEMO1 transcript expression may represent a feedback control 
mechanism. 
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We discovered that treatment of HS-rats with artesunate activates the kinase Akt, which is 
involved on inflammatory responses and cell survival.23 Activation of Akt has a number of 
beneficial effects including reduction/prevention of i) ventilation-induced lung injury,24 ii) 
sepsis-induced cardiac dysfunction,25 iii) sepsis-induced acute kidney injury,26 iv) myocardial 
ischaemia-reperfusion27 and v) HS-induced organ dysfunction.28 Activation of Akt results in 
phosphorylation and activation of eNOS at Ser117729 which enhances the formation of small 
amounts of NO, which is pivotal for the preservation of microvascular perfusion30, reducing 
organ injury.25,31 Altogether, these data support our hypothesis that activation of Akt and 
consequently activation of eNOS contribute to the attenuation of organ injury and dysfunction 
caused by HS. 
Activation of Akt was also associated with an increase in the phosphorylation of GSK-3β. 
Phosphorylation of the constitutively-active, serine-threonine kinase GSK-3β by Akt turns off 
the catalytic activity of GSK-3β23. Inhibition of GSK-3β reduces inflammation32 and organ 
injury in myocardial ischaemia,25 colitis,33 endotoxemia34,35 and haemorrhagic shock.36 Thus, 
the inactivation of GSK-3β may also contribute to the beneficial effects of artesunate in HS. 
The inhibition of GSK-3β directly inhibits NF-κB dependent gene transcription37, and NF-κB 
plays a pivotal role in inflammation38 and organ injury28,31,39. HS increased the translocation of 
NF-κB subunit p65 to the nucleus, thus, indicating its activation. The treatment of HS-rats with 
artesunate caused inactivation of GSK-3β (by phosphorylation), which was associated with 
reduced translocation of p65 subunit to the nucleus. Indeed, inhibition of NF-κB (by inhibiting 
activation of the IKK complex) reduces the organ injury/inflammation in HS.28 Thus, inhibition 
of GSK-3β and NF-κB may both importantly contribute to the observed anti-inflammatory 
effects (e.g. neutrophil recruitment into end organs such as the lung, reduction in the formation 
of pro-inflammatory cytokines; see below, prevention of the expression of iNOS, see below) of 
artesunate in HS.  
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As NF-κB regulates iNOS expression and iNOS plays an important role in the pathophysiology 
of HS,40,41 we have investigated the effects of artesunate treatment on iNOS expression in HS-
rats. HS increased the expression of iNOS in liver and kidney, and artesunate attenuated iNOS 
expression in both organs. As an excessive formation of NO by iNOS contributes to the organ 
injury in HS16,40 and sepsis,42,43,44 and also causes cellular damage and tissue injury through 
peroxynitrite formation,41 the reduction in iNOS expression may contribute to the organ 
protection afforded by artesunate. 
An increase circulating pro-inflammatory cytokines such as TNF-α and IL-6 is associated with 
organ injury/dysfunction and lethality following HS and sepsis.43,45,46,47 Elevated serum IL-6 
concentrations predict the development of organ failure in patients with trauma-haemorrhage.48 
We report here that HS results in the excessive formation of TNF-α and IL-6, and that treatment 
of HS-rats with artesunate reduced the production of these cytokines. As patients who either 
produce excessive amounts of cytokines or cannot clear them from the circulation have an 
increased risk of MOF and death,45 the reduction of circulating TNF-α and IL-6 may have 
importantly contributed to the attenuation of organ injury and dysfunction observed in HS-rats 
treated with artesunate. 
Taken together, our results show that the protective effect of artesunate in HS is associated with 
an increased activation of Akt and eNOS phosphorylation and consequently inhibition of GSK-
3β, which in turn, inhibited the translocation of NF-κB to the nucleus. This mechanism is 
supported on several levels. At a transcriptome level using pathway analysis, we find strong 
support for AKT activation on the basis of genome-wide enrichment of differential expression 
among AKT interactors. Expression of pro-inflammatory, inhibition targets of AKT, such as 
IRAK1 and FOXO4 are reduced. At the protein level, artesunate also attenuated iNOS 
expression and reduced the formation of pro-inflammatory cytokines, all of which may have 
contributed for the attenuation of organ injury and dysfunction associated with HS. Thus, the 
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use of the anti-malarial drug artesunate, which is a safe, low-cost and already-developed drug, 
could represent a therapeutic approach for the treatment and/or prevention of the organ injury 
and dysfunction associated with HS.   
Currently, here is no specific treatment for organ failure and dysfunction associated with HS, 
which is associated with a high morbidity and mortality. Thus, a safe and low cost therapeutic 
intervention, which reduces the incidence and severity of MOF may have a great impact on the 
patient quality of life and the costs of healthcare. The doses of artesunate used here (2.4 or 4.8 
mg/kg i.v. bolus injection) are very similar to those used in patients with malaria. Artesunate 
has a very good safety profile with no or minimal adverse effects in both healthy volunteers (up 
to 8 mg/kg i.v.) and patients with severe malaria (2.4 mg/kg i.v. followed by 2.4 mg/kg i.v. 
every 12 h until the patient has regained consciousness). The excellent safety profile of 
artesunate is (at least in part) due to its very short half-life in man: the intravenous injection of 
artesunate results in high, transient peak concentrations, which decline rapidly with an 
estimated half-life of 15 minutes. The concentration of the active metabolite DHA peaks within 
25 minutes of injection of artesunate, and the half-life is estimated 30 to 60 minutes. The 
metabolism of artesunate is not affected by the presence of either renal or liver failure and the 
dose of artesunate does not need to be adjusted in patients with multiple organ failure.49 Thus, 
we are planning a phase II placebo-controlled randomized clinical trial designed to evaluate the 
effects of GMP-artesunate (2.4 or 4.8 mg/kg i.v.) in 105 patients with trauma and severe 
haemorrhage. This single-centre trial will commence at the Royal London Hospital in autumn 
of 2015.  
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FIGURE LEGENDS 
 
Fig. 1. Artesunate attenuates the organ injury and dysfunction induced by HS. (A) 
creatinine clearance, (B) serum creatinine, (C) serum aspartate aminotransferase (AST), (D) 
serum alanine aminotransferase (ALT), (E) serum amylase, (F) serum lipase, (G) serum creatine 
kinase (CK) and (H) lactate of HS-rats treated with vehicle or artesunate (2.4 or 4.8 mg/kg) on 
resuscitation are shown. Sham rats were treated with vehicle or artesunate 4.8 mg/kg. Data are 
expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed 
by Bonferroni’s post hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + 
vehicle. 
Fig. 2. Artesunate attenuates MPO activity in lungs induced by HS. MPO activity in lungs 
of sham and HS-rats treated with vehicle or artesunate (2.4 or 4.8 mg/kg) on resuscitation are 
shown. Sham rats were treated with vehicle or artesunate 4.8 mg/kg. Data are expressed as 
mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by 
Bonferroni’s post hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
Fig. 3. Artesunate does not prevent the development of the circulatory failure induced by 
HS. HS-rats were treated with vehicle or artesunate (2.4 or 4.8 mg/kg) on resuscitation. Sham 
animals were used as control and received vehicle or artesunate (4.8 mg/kg). The mean arterial 
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pressure (MAP) was recorded during the whole experiment. Data are expressed as mean ± SEM. 
Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post hoc 
test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
Figure 4. Enrichr Protein Protein Interaction hub (PPI hub) analysis and core network of 
AKT1 interactor proteins constructed using Ingenuity pathway analsyis. (A) The top ten 
PPI hubs represented in the HS v HS + ART comparison are shown with combined scores in 
the HS v HS + ART and the SH v SH + ART comparisons. Combined score is based on log 
fisher exact p-value multiplied by the Z-score of the deviation from expected rank. (B) The 
network was constructed using AKT1 as a seed and all genes showing differential expression in 
SH v SH + ART and HS v HS + ART analyses. Ingenuity Molecule Activity Predictor analysis 
predicts activation of AKT1 on the basis of observed down regulation in several interactors that 
are known to be inhibited by AKT1.    
Fig. 5. Artesunate attenuates the activation of NF-κB pathway induced by HS in the liver. 
The phosphorylation of (A) Ser473 on Akt, (B) Ser1177 on eNOS, (C) Ser9 on GSK-3β and (E) 
the nuclear translocation of p65 subunit of NF-κB in the liver of sham and HS rats treated with 
vehicle or artesunate (4.8 mg/kg) on resuscitation were determined by western blotting. Protein 
expression was measured as relative optical density (O.D.), corrected for the corresponding β-
actin contents and normalized using the related sham band. Data are expressed as mean ± SEM. 
Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post hoc 
test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
Fig. 6. Artesunate attenuates the activation of NF-κB pathway induced by HS in the 
kidney. The phosphorylation of (A) Ser473 on Akt, (B) Ser1177 on eNOS, (C) Ser9 on GSK-3β 
and (E) the nuclear translocation of p65 subunit of NF-κB in the kidney of sham and HS rats 
treated with vehicle or artesunate (4.8 mg/kg) on resuscitation were determined by western 
blotting. Protein expression was measured as relative optical density (O.D.), corrected for the 
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corresponding β-actin contents and normalized using the related sham band. Data are expressed 
as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by 
Bonferroni’s post hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
Fig. 7. Artesunate attenuates iNOS expression in liver and kidney and serum TNF-α and 
IL-6 induced by HS. The iNOS expression in the liver (A) and kidney (B) of sham and HS rats 
treated with vehicle or artesunate (4.8 mg/kg) on resuscitation were determined by western 
blotting. Protein expression was measured as relative optical density (O.D.), corrected for the 
corresponding β-actin contents and normalized using the related sham band. The serum 
concentrations of (C) TNF-α and (D) IL-6 were determined by ELISA in sham and HS-rats 
treated with vehicle or artesunate (4.8 mg/kg) on resuscitation. Data are expressed as mean ± 
SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post 
hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
 
 
 
 
 
 
 
 
 
